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Letter to the editor
Risk of second cancer after testicular
cancer in Vaud and Neuchatel,
Switzerland
Patients with testicular cancer have been reported to have an
increased risk of developing new primary cancer in the contra-
lateral testis, although the extent of the excess risk remains
open to debate. The relative risk (RR) from the largest pub-
lished series ranged between 6- [1] and over 25-fold [2, 3],
reflecting in some degrees random variation, population char-
acteristic, as well as a different definition of second primary
cancers. Further, patients diagnosed with testicular cancer may
have excess risk of lymphoid neoplasms, following chemo- or
radiotherapy for the disease [1, 4].
To provide further information on the issue, we have com-
bined the datasets from the Swiss Registries of the cantons of
Vaud and Neuchatel whose populations, according to the 1990
census, were 600,000 and 160,000 inhabitants, respectively [5,
6]. Population-based incidence data have been available since
1974. The registries are tumour based, and multiple primaries
in the same person are registered separately. Both passive and
active follow-up procedures are followed, and each subsequent
item of information is used to complete the record of the
patient [7].
After exclusion of one case detected at autopsy and five at
death or by death certification alone, the present series com-
prised 745 testicular cancers (ICD-9 topography code: 186.9
[8]), including 356 seminomas (ICD-O-9 morphological code
9061-3), 317 germ-cell malignant tumours (ICD-O-9 9060,
9064-90), and 72 other or unspecified neoplasms diagnosed
between 1974 and 1996 (rate of histological verifications: 97.1%).
These persons were followed-up to the end of 1996 for the
occurrence of a second primary neoplasm, emigration, or
death, for a total of 6354.7 person-years at risk. Second
primary testicular cancers were by definition of different histo-
logical type (seminomas/germ-cell malignant tumours/other
or unspecified) as compared to primary ones (although this
may represent a conservative definition of second primaries),
and registered > 2 months after primary ones. Calculation of
expected numbers of cases were based on site-, age-, and
calendar-period specific incidence rates, multiplied by the
corresponding number of person-years at risk. The signifi-
cance of the observed :expected ratios (standardized incidence
ratio (SIR)) and their corresponding 95 percent confidence
intervals (CI) was based on the Poisson distribution [9].
Table 1 gives the observed and expected numbers of all
neoplasms and of cancers of selected sites. A total of 35 second
primary neoplasms were observed versus 24.8 expected, corre-
sponding to a SIR of 1.4, of borderline significance (95% CI:
0.98-2.0). A significant excess was observed for second testicu-
lar cancer with 6 observed versus 0.98 expected (SIR = 6.1,
96% CI: 2.2-13.3). Moderate and non-significant excesses were
observed for a few other cancer sites, too (Table 1), including
one case of leukaemia versus 0.49 expected. Excluding testis
and skin non melanoma, the SIR was 1.2 (95% CI: 0.7-1.8).
The present series is based on relatively small absolute
numbers, and on a strict and conservative definition - in terms
of histological types and time of diagnosis - of second primary
Table I. Observed (O) and expected (E) cases, and standardized
incidence ratios (SIR) of selected" subsequent cancer sites after an
initial diagnosis of testicular cancer, and corresponding overall stand-
ardized incidence ratios (SIR) and 95% confidence intervals (95% CI).
Vaud and Neuchatel. Switzerland. 1974-1996.
Site
Stomach
Colorectum
Lung
Skin, non melanoma
Prostate
Testis
Kidney
Brain
Total, all sites
All sites, minus testis
All sites, minus testis and skin
non melanoma
O
2
3
4
8
2
6
2
2
35a
29
21
E
0.8
2.0
3.6
5.9
2.0
1.0
0.6
0.5
24.8
23.8
17.9
SIR
2.5
1.5
1.1
1.4
1 0
6.1
3.5
4.2
1.4
1.2
1.2
95% CI
0.3-9.2
0.3-4.3
0.3-2.8
0.6-2.7
0 1-3 6
2.2-13.3
0.4-12.6
0 5-15.4
1.0-2.0
0.8-1.7
0.7-1.8
" Only one case was observed for cancers of the mouth or pharynx (1.8
expected), pancreas (0 5 expected), larynx (0.5 expected), skin mela-
noma (0.9 expected), leukaemias (0.5 expected), and other and unspe-
cified sites (0.4 expected).
testicular cancer. In particular, the use of different histologic
criteria for a new primary is a very strict definition, which
produces very conservative estimates of risk. Even in the
absence of information on treatment [1], this study provides,
nonetheless, further information on risk of second primary
testicular cancer, and perhaps lymphoid neoplasms, although
data are too limited for any quantitative evaluation of this issue.
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Twenty-seven authors (all but three of them American)
have contributed to the drafting of this book, which
includes thirteen chapters about digestive oncology,
aimed at emphasising treatment advances and research
developments in the field.
The contents of the volume can be divided into two
areas of interest. The main one, constituting 11 chapters,
deals with the crucial issues inherent to both classical
and innovative therapeutic strategies in management of
patients with esophageal, hepatocellular, anal (overall
overviews), exocrine pancreas, gastric (adjuvant setting),
colorectal (chemotherapy of advanced disease, adjuvant
combined therapy for rectal cancer), and metastatic
liver (surgical and locoregional treatment) carcinomas.
Two chapters focus on specific biological therapy
(cytokines, immunomodulators, monoclonal antibodies,
cancer vaccines) for bowel malignancies, and new trends
regarding disease-oriented staging and surgical ap-
proaches. Separate attention is paid to the mechanisms
involved in pharmacological resistance of colorectal
tumours. The second area, which comprises the two
concluding sections, is dedicated to a description of the
molecular genetics of pancreatic and colon cancers.
A laudable effort has been made to present the con-
tents in a clear and readable manner, providing mostly
useful information not only about current multimodal
treatment options, but also, in some sections, promising
areas of research development. For this purpose, the
authors have carefully updated the literature on sub-
jects, although in the majority of chapters the most
recent references precede by two years the publication
date of the book, which is a typical editorial drawback.
In general, the chapters are well worked out, even if on
occasion some of the contents do not fully correspond to
the objectives mentioned in the book preface. Thus,
some sections (such as those on esophageal, hepato-
cellular, pancreas and anal cancers) vary in their details
about pathological, epidemiological and clinical features.
The chapters on colorectal and gastric malignancies are
very well constructed, presenting an exhaustive analysis
of the results of most relevant pharmacological and
combined modality trials. Equally excellent is the sec-
tion dedicated to tumour resistance, which deals with
the genetic and biochemical changes influencing the
cellular response to pharmacological agents, and their
implications for innovative therapies (inhibitors of sig-
nal-transduction, angiogenesis and tissue proteinases).
The section on surgical oncology highlights the current
diagnostic options for accurate pre-operative staging,
with an interesting overview of minimally invasive and
radical approaches. There is useful information in the
chapter concerning metastatic liver tumours, which re-
views local treatment such as hepatic resection, arterial
chemotherapy, chemoembolization and cryosurgery, the
latter probably having a major impact in the near future.
The chapter on biological therapy covers the field from
an historical point of view, whereas in sections on
molecular biology more space could have been devoted
to the discussion of potential applications in patient
management.
There is already extensive literature regarding the
topics discussed in this volume. Nevertheless, it makes
the subjects interesting and sometimes attractive, having
the merit of stressing the role, often undervalued, of the
requirement of a multidisciplinary interaction in man-
agement of digestive malignant diseases. For these rea-
sons, it can be recommended to both an audience of
general oncologists and specialists in the field.
P. Saletti
Harrow
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